Expertise in
22
conditions

Dr. Denise M. Damek

Neurology
University Of Colorado Denver Hospital
12631 E 17th Ave, 
Aurora, CO 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
University Of Colorado Denver Hospital
12631 E 17th Ave, 
Aurora, CO 

Overview

Denise Damek is a Neurologist practicing medicine in Aurora, Colorado.

Dr. Damek is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 6 clinical trials. Dr. Damek is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CO

Hospital Affiliations

Uchealth Highlands Ranch Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital
Medical Center Of The Rockies

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

University of Colorado Denver Hospital
12631 E 17th Ave, Aurora, CO 80045
Other Locations
University of Colorado Hospital
1665 Aurora Ct, Aurora, CO 80045

Additional Areas of Focus

Dr. Damek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Enrollment Status: Withdrawn
Publish Date: September 21, 2022
Intervention Type: Diagnostic test
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

20 Total Publications

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Similar Doctors
Expertise in
58
conditions
Expertise in
58
conditions
Referral may be required

University Of Colorado Hospital Authority

1635 Aurora Ct, 
Aurora, CO 
 (0.1 miles away)
720-848-2080
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Wicklund is a Neurologist practicing medicine in Aurora, Colorado. Dr. Wicklund is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Limb-Girdle Muscular Dystrophy, Inclusion Body Myositis, Limb-Girdle Muscular Dystrophy Type 2I, and Paramyotonia Congenita. Dr. Wicklund is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

University Of Colorado Hospital Authority

1635 Aurora Ct, 
Aurora, CO 
 (0.1 miles away)
720-848-2080
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benzi Kluger is a Neurologist practicing medicine in Aurora, Colorado. Dr. Kluger is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, and Gastrostomy.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (0.3 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Demarest is a Neurologist practicing medicine in Aurora, Colorado. Dr. Demarest is highly rated in 16 conditions, according to our data. His clinical expertise encompasses West Syndrome, Spasmus Nutans, Epilepsy, and Rett Syndrome. Dr. Demarest is currently accepting new patients.

Frequently Asked Questions about Dr. Denise M. Damek

How do I make an appointment with Dr. Denise M. Damek?

You can book an appointment with Dr. Denise M. Damek by calling their office at 720-848-0300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Denise M. Damek a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Denise M. Damek is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Denise M. Damek specialize in?

While Dr. Denise M. Damek is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Denise M. Damek participate in research or clinical trials?

Yes. Dr. Denise M. Damek has published 20 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Denise M. Damek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Denise M. Damek accept my insurance?

Dr. Denise M. Damek accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-848-0300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Damek's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 7 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile